UK losing foreign direct investment in life sciences race
AI-Generated Summary
A new industry report indicates a significant decline in foreign direct investment (FDI) into the UK's life sciences sector, falling by 58% since 2017, alongside a slowdown in pharmaceutical R&D. Pharmaceutical companies, including AstraZeneca and Eli Lilly, attribute this trend to low investment, poor patient access to new medicines, and unpredictable NHS clawbacks. This situation jeopardizes the UK's position as a global leader in a key growth sector, despite its robust research infrastructure.
In a nutshell
This development highlights a critical tension between the UK government's efforts to manage healthcare costs and its ambition to attract investment and foster innovation in vital sectors. The ongoing conflict between policy decisions and industry incentives could impede the nation's long-term economic growth and its global competitiveness in life sciences.
Source: The Sunday Times
